- Home
- JILL vs SGMT Comparison
JILL vs SGMT Comparison
Compare JILL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- SGMT
- Stock Information
- Founded
- JILL 1959
- SGMT 2006
- Country
- JILL United States
- SGMT United States
- Employees
- JILL N/A
- SGMT N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- SGMT
- Sector
- JILL Consumer Discretionary
- SGMT
- Exchange
- JILL Nasdaq
- SGMT Nasdaq
- Market Cap
- JILL 233.1M
- SGMT 230.3M
- IPO Year
- JILL 2017
- SGMT 2023
- Fundamental
- Price
- JILL $18.17
- SGMT $7.03
- Analyst Decision
- JILL Buy
- SGMT Strong Buy
- Analyst Count
- JILL 3
- SGMT 7
- Target Price
- JILL $18.00
- SGMT $26.57
- AVG Volume (30 Days)
- JILL 120.3K
- SGMT 587.6K
- Earning Date
- JILL 09-03-2025
- SGMT 08-13-2025
- Dividend Yield
- JILL 1.78%
- SGMT N/A
- EPS Growth
- JILL N/A
- SGMT N/A
- EPS
- JILL 2.39
- SGMT N/A
- Revenue
- JILL $601,713,000.00
- SGMT N/A
- Revenue This Year
- JILL $1.16
- SGMT N/A
- Revenue Next Year
- JILL $1.46
- SGMT N/A
- P/E Ratio
- JILL $7.54
- SGMT N/A
- Revenue Growth
- JILL N/A
- SGMT N/A
- 52 Week Low
- JILL $13.36
- SGMT $1.73
- 52 Week High
- JILL $30.40
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- JILL 66.54
- SGMT 38.57
- Support Level
- JILL $15.97
- SGMT $7.01
- Resistance Level
- JILL $18.38
- SGMT $7.68
- Average True Range (ATR)
- JILL 0.82
- SGMT 0.50
- MACD
- JILL 0.15
- SGMT -0.02
- Stochastic Oscillator
- JILL 92.03
- SGMT 37.50
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.